Tower Research Capital LLC (Trc) Gain Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,064 shares of GANX stock, worth $5,841. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,064
Previous 945
118.41%
Holding current value
$5,841
Previous $1,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding GANX
# of Institutions
42Shares Held
5.02MCall Options Held
10.3KPut Options Held
0-
Jones Financial Companies Lllp677KShares$1.92 Million0.0% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.67 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.6 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA534KShares$1.51 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il374KShares$1.06 Million0.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $33.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...